Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial.
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
publication date
- August 30, 2025